<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement. Abbisko Cayman’s subsidiary Abbisko Therapeutics has reported that results from its global Phase 3 MANEUVER trial of pimicotinib in tenosynovial giant cell tumour have been published in The Lancet, underscoring the quality and robustness of its clinical research. The 94-patient, multicenter study showed significant efficacy and a generally favorable safety profile, supporting China’s 2025 approval, ongoing U.S. and other regulatory reviews, and Merck’s plans to commercialize the drug globally. The publication in a leading international medical journal enhances Abbisko’s academic and clinical standing, potentially strengthening its competitive position in targeted oncology and rare disease treatments. For stakeholders, the data validation and existing China approval highlight near-term commercial prospects, though the company cautions that ultimate global commercialization outcomes remain uncertain and subject to regulatory decisions and market execution. The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page. More about Abbisko Cayman Limited Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biopharmaceutical industry with a focus on innovative oncology and immunology therapies. The group develops small-molecule drugs such as pimicotinib, a highly selective CSF-1R inhibitor targeting tenosynovial giant cell tumour, and partners with global pharma major Merck for worldwide commercialization. Average Trading Volume: 1,568,817 Technical Sentiment Signal: Buy Current Market Cap: HK$8.08B </div>

516500

02256

513120

Abbisko Cayman Limited's subsidiary, Abbisko Therapeutics, announced the publication of its Phase 3 MANEUVER trial results for pimicotinib in The Lancet. The study demonstrated significant efficacy and a favorable safety profile in treating tenosynovial giant cell tumor, supporting regulatory reviews in China and the U.S. The publication enhances Abbisko's standing in oncology, with potential commercial prospects, although global commercialization remains uncertain. The latest analyst rating for Abbisko Cayman Limited (HK:2256) is a Hold with a price target of HK$13.00.

Tip Ranks

ChinaAMC CSI Biotechnology Theme ETF

ABBISKO-B

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication